1. Market Research
  2. > Healthcare
  3. > Pathology Market Trends
  4. > Xarelto (Acute Coronary Syndrome) - Forecast and Market Analysis to 2023

Xarelto (Acute Coronary Syndrome) - Forecast and Market Analysis to 2023

  • July 2014
  • -
  • GlobalData
  • -
  • 91 pages

Summary

Table of Contents

Xarelto (Acute Coronary Syndrome) - Forecast and Market Analysis to 2023

Summary

GlobalData has released its new PharmaPoint Drug Evaluation report, “Xarelto (Acute Coronary Syndrome) - Forecast and Market Analysis to 2023”. The current ACS market - primarily comprised of antithrombotics, antihypertensives, and statins - is flush with well-established standard-of-care therapies, many of which are generic. Therefore, the pipeline therapies that show the most promise exploit novel mechanisms of action and target orphan biochemical pathways. The ACS market will be driven by an aging population with a preponderance of lifestyle-based diseases, such as obesity, and the growing prevalence of metabolic disorders such as diabetes. The expansion of biologics into the ACS mainstream during the ten year forecast period is expected to significantly and fundamentally alter the ACS market, both medically and financially.

Xarelto was approved in the EU for the prevention of non-valvular atrial fibrillation (AF)-related stroke and systemic embolism, and for the treatment of deep vein thrombosis (DVT). On July 1, 2011, Xarelto was approved in the US to reduce the risk of blood clots, DVT, and pulmonary embolism (PE) following hip or knee replacement surgery, and in November of the same year, it was approved for stroke prevention in patients with non-valvular AF.

Scope

- Overview of ACS, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
- Detailed information on Aricept including product description, safety and efficacy profiles as well as a SWOT analysis.
- Sales forecast for Aricept for the top seven countries from 2013 to 2023.
- Sales information covered for the US, France, Germany, Italy, Spain, the UK and Japan.

Reasons to buy

- Understand and capitalize by identifying products that are most likely to ensure a robust return
- Stay ahead of the competition by understanding the changing competitive landscape for ACS
- Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
- Make more informed business decisions from insightful and in-depth analysis of Aricept performance
- Obtain sales forecast for Aricept from 2013-2023 in top seven countries (the US, France, Germany, Italy, Spain, the UK and Japan)

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 60 Million searchable statistics with tables, figures & datasets
  • More than 25,000 trusted sources
Get This Report
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers
Acute coronary syndrome (ACS)- Market Insights, Epidemiology and Market Forecast-2023

Acute coronary syndrome (ACS)- Market Insights, Epidemiology and Market Forecast-2023

  • $ 4950
  • Industry report
  • January 2017
  • by Delve Insight

Note*: This report requires 5 business days to complete. DelveInsight’s Acute coronary syndrome (ACS) - Market Insights, Epidemiology and Market Forecast-2023” Reports provides an overview of the ...

Acute coronary syndrome (ACS) - Epidemiology Forecast To 2023

Acute coronary syndrome (ACS) - Epidemiology Forecast To 2023

  • $ 2750
  • Industry report
  • January 2017
  • by Delve Insight

DelveInsight “Acute coronary syndrome (ACS) - Epidemiology Forecast To 2023” provides an overview of the epidemiology trends of Acute coronary syndrome (ACS) in seven major markets (US, France, Germany, ...

Acute Coronary Syndrome Global Clinical Trials Review, H1, 2017

Acute Coronary Syndrome Global Clinical Trials Review, H1, 2017

  • $ 2500
  • Industry report
  • February 2017
  • by GlobalData

Acute Coronary Syndrome Global Clinical Trials Review, H1, 2017 Summary GlobalData’s clinical trial report, “Acute Coronary Syndrome Global Clinical Trials Review, H1, 2017” provides an overview ...

Cardiac Markers

June 2016 $ 1995

ref:plp2014

Reportlinker.com © Copyright 2017. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.